세계의 롱리드 시퀀싱 시장 : 시장 규모, 점유율, 동향 - 제공별, 기술별, 워크플로우별, 용도별, 사용법별, 최종사용자별, 지역별 - 예측(-2029년)

The long-read sequencing market is expected to reach USD 3,129 million in 2029 from USD 758 million in 2024, at a CAGR of 32.8% during the forecast period.

Growth in the long-read sequencing market is mainly driven by factors like increasing collaborations between academic institutions and industry players, decreased cost of sequencing, and continuous technological advancements in long-read sequencing. Moreover, the application of LRS like de novo genome assembly, structural variant detection, transcriptomics, and epigenetics is supporting the market growth. However, the initial cost concern to set up the equipment is impacting the growth of the long-read sequencing market.

"The consumables segment accounted for the largest share by offerings segment in the long-read sequencing market in 2023"

The long-read sequencing market is segmented into consumables, instruments, and services in 2023. The consumables is the segment with the largest share in offerings. The large share of consumables is due to their role in sample preparation, sequencing, and data analysis part of long-read sequencing. As the demand for sequencing increases, it supports the demand for the consumables segment, driving its growth in the market. Still, the instrument segment held the second-largest market share.

"The academic & research institutes segment accounted for the largest share by end-user segment in the long-read sequencing market in 2023"

The long-read sequencing market is segmented into academic & research institutes, pharmaceutical & biotechnologies companies, hospitals, clinics & diagnostics laboratories, and other end users. The academic & research institutes are the segment with the largest share in the end-user segment in 2023. The large share of academic & research institutes is due to the increased demand for whole genome sequencing products, and increased genomics research. However, the pharmaceutical & biotechnological companies accounted for the second largest share in the segment.

"The Asia Pacific region is growing at the highest CAGR in the long-read sequencing market from 2024 to 2029."

The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the large scale of population genomics projects, and the demand for precision medicines is supporting the growth. Further, the rising prevalence of chronic diseases is attributed to the aging population of countries such as Japan, and China. These is supporting the adoption of sequencing technologies in healthcare prognosis and treatment driving the market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

• Oxford Nanopore Technologies plc. (UK)
• PacBio (US)
• Illumina, Inc. (US)
• Agilent Technologies, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• 10X Genomics, Inc. (US)
• QIAGEN (Germany)
• BGI Group (China)
• Takara Bio Inc. (Japan)
• Azenta US, Inc. (US)
• Revvity, Inc. (US)
• Danaher Corporation (US)
• Novogene Co., Ltd. (China)
• New England Biolabs (US)
• BaseClear BV (Netherlands)
• Element Biosciences (US)
• Grandomics (China)
• CD Genomics (US)
• Sage Sciences, Inc. (US)
• EdenRoc Sciences (US)

Research Coverage:

This research report categorizes the long-read sequencing market by offerings (instruments, consumables, and services), technology (single-molecule real-time sequencing, nanopore sequencing, and synthetic long-read sequencing), workflow (sample preparation, sequencing, and data analysis), application (whole genome sequencing, metagenomics, epigenetics, targeted sequencing, whole exome sequencing, and other applications), usage (research and clinical), end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals, clinics & diagnostic Labs, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the long-read sequencing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as collaborations, expansions, agreements, and recent developments associated with the long-read sequencing market. Competitive analysis of top players and upcoming startups in the long-read sequencing market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall long-read sequencing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Technological advancements in genome sequencing, Increased prevalence of complex and rare genetic disorders, and growing demand for high-quality throughput screening), restraints (High investments to develop long read sequencing technologies, Technical Limitations of existing technology), opportunities (Rising demand for long-read sequencing in clinical genomics, and expanding applications of long-read sequencing), and challenges (challenges associated with data preservation, analysis, and validation) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched services of the long-read sequencing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the long-read sequencing market
• Competitive Assessment: Oxford Nanopore Technologies plc. (UK), PacBio (US), Illumina, Inc. (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), 10X Genomics, Inc. (US), QIAGEN (Germany), BGI Group (China), Takara Bio Inc. (Japan), Azenta US, Inc. (US), Revvity, Inc. (US), Danaher Corporation (US), Novogene Co., Ltd. (China), New England Biolabs (US), BaseClear BV (Netherlands), Element Biosciences (US), Grandomics (China), CD Genomics (US), Sage Sciences, Inc. (US), and EdenRoc Sciences (US) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET SIZE ESTIMATION
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LONG-READ SEQUENCING MARKET OVERVIEW
• 4.2 ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY OFFERING
• 4.3 LONG-READ SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 LONG-READ SEQUENCING MARKET SHARE, BY END USER, 2023

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Emerging technological advancements
    • 5.2.1.2 Increasing prevalence of complex and rare genetic disorders
    • 5.2.1.3 Growing demand for high-throughput sequencing
    • 5.2.1.4 Expanding applications of long-read sequencing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High investment cost
    • 5.2.2.2 Technical limitations of existing technologies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising adoption in clinical genomics
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Data preservation, analysis, and validation issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 REGULATORY SCENARIO
  • 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGICAL ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Single-molecule real-time sequencing
    • 5.6.1.2 Nanopore sequencing
    • 5.6.1.3 Synthetic long-read sequencing
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Next-generation sequencing combined with artificial intelligence
    • 5.6.2.2 Single-cell sequencing
    • 5.6.2.3 Polymerase chain reaction
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Sample preparation technologies
    • 5.6.3.2 Data analysis
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY OFFERING
  • 5.7.2 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENT
  • 5.7.3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY CONSUMABLE
  • 5.7.4 AVERAGE SELLING PRICE OF KEY PLAYERS, BY SERVICE
  • 5.7.5 AVERAGE SELLING PRICE, BY REGION
• 5.8 PATENT ANALYSIS
• 5.9 SUPPLY CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
• 5.11 KEY CONFERENCES & EVENTS, 2024-2025
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.2 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 THREAT OF SUBSTITUTES
  • 5.12.6 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA, BY END USER
• 5.14 INVESTMENT & FUNDING SCENARIO
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 ENHANCED DETECTION OF AMYOTROPHIC LATERAL SCLEROSIS USING PACBIO SINGLE-MOLECULE, REAL-TIME SEQUENCING
  • 5.15.2 IMPROVED DIAGNOSIS OF RARE DISEASES WITH LONG-READ WHOLE-GENOME SEQUENCING
• 5.16 IMPACT OF AI ON LONG-READ SEQUENCING MARKET

6 LONG-READ SEQUENCING MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 LARGE NUMBER OF PLAYERS OPERATING IN CONSUMABLES SPACE TO PROPEL DEMAND
• 6.3 INSTRUMENTS
  • 6.3.1 ADVANCEMENTS IN LONG-READ SEQUENCING TECHNOLOGY TO BOOST MARKET GROWTH
• 6.4 SERVICES
  • 6.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS TO FAVOR MARKET GROWTH

7 LONG-READ SEQUENCING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 NANOPORE SEQUENCING
  • 7.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET GROWTH
• 7.3 SINGLE-MOLECULE REAL-TIME SEQUENCING
  • 7.3.1 HIGHLY ACCURATE LONG READS BY REPEATEDLY SEQUENCING CIRCULARIZED DNA TO DRIVE DEMAND
• 7.4 SYNTHETIC LONG-READ SEQUENCING
  • 7.4.1 GROWING DEMAND FOR DETAILED AND COMPREHENSIVE GENOMIC DATA IN AREAS SUCH AS CLINICAL GENOMICS TO BOOST MARKET

8 LONG-READ SEQUENCING MARKET, BY WORKFLOW

• 8.1 INTRODUCTION
• 8.2 SEQUENCING
  • 8.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET GROWTH
• 8.3 SAMPLE PREPARATION
  • 8.3.1 DEVELOPMENT OF ADVANCED LIBRARY PREPARATION SOLUTIONS TO BOOST MARKET
• 8.4 DATA ANALYSIS
  • 8.4.1 DEVELOPMENT OF ADVANCED BIOINFORMATICS SOLUTIONS TO FAVOR MARKET GROWTH

9 LONG-READ SEQUENCING MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 WHOLE-GENOME SEQUENCING
  • 9.2.1 INCREASING USE OF WGS IN RARE DISEASE RESEARCH TO DRIVE MARKET GROWTH
• 9.3 TARGETED SEQUENCING
  • 9.3.1 RISING DEMAND FOR LONG-READ SEQUENCING IN DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH
• 9.4 METAGENOMICS
  • 9.4.1 GROWING DEMAND FOR HIGH-RESOLUTION AND ACCURATE METAGENOMIC DATA TO FUEL GROWTH
• 9.5 EPIGENETICS
  • 9.5.1 ADVANTAGES OF LRS IN EPIGENETICS STUDIES TO BOOST DEMAND
• 9.6 WHOLE-EXOME SEQUENCING
  • 9.6.1 GROWING DEMAND FOR PRECISION GENETICS TO FAVOR MARKET GROWTH
• 9.7 OTHER APPLICATIONS

10 LONG-READ SEQUENCING MARKET, BY USAGE

• 10.1 INTRODUCTION
• 10.2 RESEARCH USAGE
  • 10.2.1 RISING RESEARCH COLLABORATIONS TO BOOST MARKET GROWTH
• 10.3 CLINICAL USAGE
  • 10.3.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH

11 LONG-READ SEQUENCING MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 ACADEMIC & RESEARCH INSTITUTES
  • 11.2.1 ACADEMIC & RESEARCH INSTITUTES TO DOMINATE MARKET DURING FORECAST PERIOD
• 11.3 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 11.3.1 GROWING COLLABORATIONS BETWEEN LRS PLAYERS AND PHARMA-BIOTECH COMPANIES TO DRIVE GROWTH
• 11.4 HOSPITALS, CLINICS, AND DIAGNOSTIC LABS
  • 11.4.1 RISING DEMAND FOR LONG-READ SEQUENCING IN HOSPITALS & CLINICS TO SUPPORT GROWTH
• 11.5 OTHER END USERS

12 LONG-READ SEQUENCING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 US
    • 12.2.1.1 US to dominate North American long-read sequencing market during forecast period
  • 12.2.2 CANADA
    • 12.2.2.1 Increasing government initiatives in genomics research to aid market growth
• 12.3 EUROPE
  • 12.3.1 GERMANY
    • 12.3.1.1 Increased funding for genomic development and application to favor market growth
  • 12.3.2 UK
    • 12.3.2.1 Favorable NHS funding and increased number of patients with rare genetic diseases to spur market growth
  • 12.3.3 FRANCE
    • 12.3.3.1 Increasing government investment in genomics and proteomics research to augment market growth
  • 12.3.4 ITALY
    • 12.3.4.1 Developed research infrastructure and increased genomics investment to fuel market growth
  • 12.3.5 SPAIN
    • 12.3.5.1 Advancements in translational and personalized medicine sector to boost market growth
  • 12.3.6 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 CHINA
    • 12.4.1.1 Favorable regulatory reforms and high patient population to aid market growth
  • 12.4.2 JAPAN
    • 12.4.2.1 Technological advancements and high government investments in biotechnology to augment market growth
  • 12.4.3 INDIA
    • 12.4.3.1 Favorable government initiatives for genomics research to drive market
  • 12.4.4 SOUTH KOREA
    • 12.4.4.1 Rising government investments in cancer treatments and precision medicine to support market growth
  • 12.4.5 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 BRAZIL
    • 12.5.1.1 Increased public and private investments in sequencing technologies to spur market growth
  • 12.5.2 MEXICO
    • 12.5.2.1 Growing prevalence of chronic disease and increasing geriatric population to support market growth
  • 12.5.3 ARGENTINA
    • 12.5.3.1 Rising healthcare investments and increasing focus on public health services to propel market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 GCC COUNTRIES
    • 12.6.1.1 Saudi Arabia
      • 12.6.1.1.1 High government healthcare expenditure and technological advancements to boost market growth
    • 12.6.1.2 UAE
      • 12.6.1.2.1 Increasing R&D investment and growing healthcare infrastructure to aid market growth
    • 12.6.1.3 Rest of GCC Countries
  • 12.6.2 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET GROWTH

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 13.3 REVENUE ANALYSIS
• 13.4 MARKET SHARE ANALYSIS
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Offering footprint
    • 13.5.5.4 Application footprint
    • 13.5.5.5 Technology footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 13.7 COMPANY VALUATION & FINANCIAL METRICS
• 13.8 BRAND/SERVICE COMPARISON
  • 13.8.1 OXFORD NANOPORE TECHNOLOGIES PLC
  • 13.8.2 PACBIO
  • 13.8.3 ILLUMINA, INC.
  • 13.8.4 AGILENT TECHNOLOGIES, INC.
  • 13.8.5 THERMO FISHER SCIENTIFIC INC.
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 DEALS
  • 13.9.2 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 OXFORD NANOPORE TECHNOLOGIES PLC
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products & services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 PACBIO
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products & services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product & service launches
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
      • 14.1.2.3.4 Other developments
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 ILLUMINA, INC.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products & services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 AGILENT TECHNOLOGIES, INC.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products & services offered
  • 14.1.5 THERMO FISHER SCIENTIFIC INC.
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products & services offered
  • 14.1.6 10X GENOMICS, INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products & services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches
  • 14.1.7 QIAGEN
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products & services offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Expansions
  • 14.1.8 BGI GROUP
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products & services offered
  • 14.1.9 AZENTA US, INC.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products & services offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Expansions
  • 14.1.10 TAKARA BIO INC.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products & services offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Deals
  • 14.1.11 NOVOGENE CO., LTD.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products & services offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Other developments
  • 14.1.12 REVVITY INC.
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products & services offered
  • 14.1.13 DANAHER CORPORATION
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products & services offered
  • 14.1.14 NEW ENGLAND BIOLABS
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products & services offered
  • 14.1.15 BASE CLEAR BV
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products & services offered
• 14.2 OTHER PLAYERS
  • 14.2.1 ELEMENT BIOSCIENCES
  • 14.2.2 GRANDOMICS
  • 14.2.3 CD GENOMICS
  • 14.2.4 SAGE SCIENCES, INC.
  • 14.2.5 EDENROC SCIENCES

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS